For many respiratory pathologies an unmet therapeutic need exists. Non-invasive pulmonary administration of small interfering RNA (siRNA) enables direct delivery into the lung tissue, but clinical translation is hampered by poor delivery in lung target cells. This project aims to optimize a hybrid nanoformulation composed of pulmonary surfactant for efficient siRNA delivery via inhalation therapy.